RGT-264

N/A

Report date: 2024/08/02 20:01:06
NME

Base Information

Drug NameRGT-264
Drug Alias NameRGT-264RGT264
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMitogen-activated protein kinase kinase kinase kinase 1 inhibitors
TargetsMitogen-activated protein kinase kinase kinase kinase 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesQILU Regor Therapeutics Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesQILU Regor Therapeutics IncRegor Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A